Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo.
Kang K, Schrump D, Thomas A, Schalper K, Saunthararajah Y, Velcheti V. Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo. Journal Of Clinical Oncology 2017, 35: 11552-11552. DOI: 10.1200/jco.2017.35.15_suppl.11552.Peer-Reviewed Original ResearchT cellsC57/BL6 miceAbsolute lymphocyte countAnti-PD1 therapyRegulatory T cellsTumor-Infiltrating LymphocytesImmune memory effectTumor-bearing miceDNMT1 depletionMost NSCLCNSCLC responsePharmacologic rationaleG-MDSCSolid cancer tissuesImmunotherapeutic effectsLymphocyte countMedian survivalIFNγ expressionInfiltrating lymphocytesSurvival improvementMAGE-A3BL6 miceLung invasionAntigen presentationMAGE-A1